Sign in Subscribe
Cancer

Unlocking Potential: New Cancer Gene Therapy Study Unveils Groundbreaking Nanoformulations

Strategic Insights

— 1 min read

Scientists at the Institute of National Importance have made significant advancements in cancer gene therapy with the development of nanoformulations of paclitaxel (PTX), a potent anticancer drug. These cutting-edge formulations aim to overcome the limitations of traditional PTX delivery, which is plagued by low aqueous solubility, limited oral bioavailability, and nonlinear pharmacokinetics. The new nanoformulations, including nanoparticles, liposomes, micelles, and nanoemulsions, show promise in mitigating organ toxicities and hypersensitivity reactions, paving the way for a safer and more effective cancer treatment.

Key Takeaways:

  • Paclitaxel (PTX) is a first-line cancer drug candidate due to its potency and profound anticancer potential.
  • Traditional PTX delivery is limited by low aqueous solubility (10-20 mg/L), limited oral bioavailability (approximately 10%), and nonlinear pharmacokinetics.
  • The development of nanoformulations of PTX addresses the limitations of traditional delivery, offering targeted delivery and improved efficacy.
  • Nanoformulations include various types, such as nanoparticles, liposomes, micelles, and nanoemulsions, which display enhanced performance in cancer treatment.
  • The Institute of National Importance and its research team have been pioneering efforts in developing innovative drug delivery strategies for PTX.
  • Funding for this research was provided by multiple organizations, including the Indian Council of Medical Research (ICMR), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India, Parkinson's disease, and diabetes at NIPER-Ahmedabad, Science and Engineering Research Board, Department of Science & Technology (India), Indian Council of Medical Research (ICMR), Science Engineering Research Board (SERB), India, Gujarat State Biotechnology Mission (GSBTM).
  • Additional authors contributing to this significant research include Anuja Muley, Aniket Navale, and Rachna Gupta.

Statistics:

  • 10-20 mg/L: The aqueous solubility of paclitaxel (PTX).
  • 10%: The limited oral bioavailability of traditional PTX delivery.
  • 33: The page number of the news report published in Cancer Weekly.
  • 1155 16TH St, NW, Washington, DC 20036, USA: The address of ACS Omega, the publisher of the research report "nano-paclitaxel" Unlocking Potential and Redefining Cancer Chemotherapy.

Sources:

  • ACS Omega, 2025.
  • Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA.
  • NewsRx LLC, 2025.
  • Cancer Weekly, July 29, 2025, p 33.

Read more